Discordant Brucella melitensis antigens yield cognate CD8 T cells in vivo

Infection and Immunity

Volumn 78, Issue 1, 2010, Pages 168-176

  Durward, Marina A ^a   Harms, Jerome ^b   Magnani, Diogo M ^b   Eskra, Linda ^b   Splitter, Gary A ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLTYROSYLCYSTEINYLISOLEUCYLASPARAGINYLSERYLALANYLSERYLLEUCINE; ASPARAGINYLGLYCYLSERYLSERYLSERYLMETHIONYLALANYLTHREONYLVALINE; BACTERIAL ANTIGEN; BRUCELLA VACCINE; EPITOPE; GAMMA INTERFERON; H2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IN VIVO STUDY; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; BRUCELLA MELITENSIS; BRUCELLOSIS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; PROTEIN BINDING;

EID: 73449121465     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00994-09     Document Type: Article

References (65)

1. Abtahi, H., A. H. Salmanian, S. Rafati, G. B. Nejad, M. Saffari, A. Ghazavi, and G. Mosayebi. 2008. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pak. J. Biol. Sci. 11:2472-2477.
2. Al Dahouk, S., V. Jubier-Maurin, H. C. Scholz, H. Tomaso, W. Karges, H. Neubauer, and S. Kohler. 2008. Quantitative analysis of the intramacrophagic Brucella suis proteome reveals metabolic adaptation to late stage of cellular infection. Proteomics 8:3862-3870.
3. Al-Mariri, A., A. Tibor, P. Mertens, X. De Bolle, P. Michel, J. Godefroid, K. Walravens, and J. J. Letesson. 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. 69:4816-4822.
4. Allen, T. M., B. R. Mothe, J. Sidney, P. Jing, J. L. Dzuris, M. E. Liebl, T. U. Vogel, D. H. O'Connor, X. Wang, M. C. Wussow, J. A. Thomson, J. D. Altman, D. I. Watkins, and A. Sette. 2001. CD8 lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J. Virol. 75:738-749.
5. Arenas-Gamboa, A. M., T. A. Ficht, M. M. Kahl-McDonagh, G. Gomez, and A. C. Rice-Ficht. 2009. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect. Immun. 77:877-884.
6. Arenas-Gamboa, A. M., T. A. Ficht, M. M. Kahl-McDonagh, and A. C. Rice-Ficht. 2008. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect. Immun. 76:2448-2455.
7. Baldwin, C. L., and R. Goenka. 2006. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit. Rev. Immunol. 26:407-442.
8. Capasso, L. 2002. Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. J. Infect. 45:122-127.
9. + T helper 1 response that protects against Brucella melitensis infection. Infect. Immun. 73:8079-8088.
10. Cassataro, J., C. A. Velikovsky, S. de la Barrera, S. M. Estein, L. Bruno, R. Bowden, K. A. Pasquevich, C. A. Fossati, and G. H. Giambartolomei. 2005. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73:6537-6546.
11. Celli, J., and J. P. Gorvel. 2004. Organelle robbery: Brucella interactions with the endoplasmic reticulum. Curr. Opin. Microbiol. 7:93-97.
12. Cherwonogrodzky, J. W. 1993. Brucella antigens: old dogmas, new concepts. Rev. Latinoam. Microbiol. 35:339-344.
13. Corbeil, L. B., K. Blau, T. J. Inzana, K. H. Nielsen, R. H. Jacobson, R. R. Corbeil, and A. J. Winter. 1988. Killing of Brucella abortus by bovine serum. Infect. Immun. 56:3251-3261.
14. Corbel, M. J. 1997. Brucellosis: an overview. Emerg. Infect. Dis. 3:213-221.
15. Cosgrove, S. E., T. M. Perl, X. Song, and S. D. Sisson. 2005. Ability of physicians to diagnose and manage illness due to category A bioterrorism agents. Arch. Intern. Med. 165:2002-2006.
16. D'Anastasio, R., B. Zipfel, J. Moggi-Cecchi, R. Stanyon, and L. Capasso. 2009. Possible brucellosis in an early hominin skeleton from sterkfontein, South Africa. PLoS ONE 4:e6439.
17. Estein, S. M., M. A. Fiorentino, F. A. Paolicchi, M. Clausse, J. Manazza, J. Cassataro, G. H. Giambartolomei, L. M. Coria, V. Zylberman, C. A. Fossati, R. Kjeken, and F. A. Goldbaum. 2009. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine 27:6704-6711.
18. Eze, M. O., L. Yuan, R. M. Crawford, C. M. Paranavitana, T. L. Hadfield, A. K. Bhattacharjee, R. L. Warren, and D. L. Hoover. 2000. Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect. Immun. 68:257-263.
19. Fernandes, D. M., X. Jiang, J. H. Jung, and C. L. Baldwin. 1996. Comparison of T-cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS Immunol. Med. Microbiol. 16:193-203.
20. Franco, M. P., M. Mulder, R. H. Gilman, and H. L. Smits. 2007. Human brucellosis. Lancet Infect. Dis. 7:775-786.
21. Harms, J. S., M. A. Durward, D. M. Magnani, and G. A. Splitter. 2009. Evaluation of recombinant invasive, non-pathogenic Escherichia coli as a vaccine vector against the intracellular pathogen, Brucella. J. Immune Based Ther. Vaccines 7:1.
22. He, Y., R. Vemulapalli, A. Zeytun, and G. G. Schurig. 2001. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infect. Immun. 69:5502-5508.
23. + T-cell responses with distinct clonotype and epitope specificity. J. Immunol. 183:2425-2434.
24. Huang, L. Y., K. J. Ishii, S. Akira, J. Aliberti, and B. Golding. 2005. Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J. Immunol. 175:3964-3970.
25. Ingulli, E. 2007. Tracing tolerance and immunity in vivo by CFSE labeling of administered cells. Methods Mol. Biol. 380:365-376.
26. Jiang, X., and C. L. Baldwin. 1993. Effects of cytokines on intracellular growth of Brucella abortus. Infect. Immun. 61:124-134.
27. Ko, J., and G. A. Splitter. 2003. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin. Microbiol. Rev. 16:65-78.
28. Lapaque, N., I. Moriyon, E. Moreno, and J. P. Gorvel. 2005. Brucella lipopolysaccharide acts as a virulence factor. Curr. Opin. Microbiol. 8:60-66.
29. López-Goñi, I., and I. Moriyón. 2004. Brucella: molecular and cellular biology. Horizon Bioscience, Wymondham, England.
30. Magnani, D. M., J. S. Harms, M. A. Durward, and G. A. Splitter. 2009. Nondividing, but metabolically active gamma-irradiated brucellae are protective against virulent Brucella melitensis challenge in mice. Infect. Immun. 77:5181-5189.
31. Memish, Z. A., and H. H. Balkhy. 2004. Brucellosis and international travel. J. Travel Med. 11:49-55.
32. Montaraz, J. A., and A. J. Winter. 1986. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infect. Immun. 53:245-251.
33. Mora, M., C. Donati, D. Medini, A. Covacci, and R. Rappuoli. 2006. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 9:532-536.
34. Moriyon, I., M. J. Grillo, D. Monreal, D. Gonzalez, C. Marin, I. Lopez-Goni, R. C. Mainar-Jaime, E. Moreno, and J. M. Blasco. 2004. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35:1-38.
35. Reference deleted.
36. Murphy, E. A., M. Parent, J. Sathiyaseelan, X. Jiang, and C. L. Baldwin. 2001. Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol. Med. Microbiol. 32:85-88.
37. Nicoletti, P. 1990. Vaccination against Brucella. Adv. Biotechnol. Processes 13:147-168.
38. Noviello, S., R. Gallo, M. Kelly, R. J. Limberger, K. DeAngelis, L. Cain, B. Wallace, and N. Dumas. 2004. Laboratory-acquired brucellosis. Emerg. Infect. Dis. 10:1848-1850.
39. + type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur. J. Immunol. 25:2551-2557.
40. Oliveira, S. C., and G. A. Splitter. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14:959-962.
41. Olle-Goig, J. E., and J. Canela-Soler. 1987. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers. Am. J. Public Health 77:335-338.
42. Oseroff, C., B. Peters, V. Pasquetto, M. Moutaftsi, J. Sidney, V. Panchanathan, D. C. Tscharke, B. Maillere, H. Grey, and A. Sette. 2008. Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J. Immunol. 180:7193-7202.
43. Ottones, F., J. Dornand, A. Naroeni, J. P. Liautard, and J. Favero. 2000. V gamma 9V delta 2 T cells impair intracellular multiplication of Brucella suis in autologous monocytes through soluble factor release and contact-dependent cytotoxic effect. J. Immunol. 165:7133-7139.
44. Pappas, G., P. Panagopoulou, L. Christou, and N. Akritidis. 2006. Biological weapons. Cell. Mol. Life Sci. 63:2229-2236.
45. Pappas, G., P. Papadimitriou, N. Akritidis, L. Christou, and E. V. Tsianos. 2006. The new global map of human brucellosis. Lancet Infect. Dis. 6:91-99.
46. Peters, B., and A. Sette. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinform. 6:132.
47. Pruitt, K. D., T. Tatusova, and D. R. Maglott. 2007. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 35:D61-D65.
48. Purcell, A. W., J. McCluskey, and J. Rossjohn. 2007. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6:404-414.
49. Rappuoli, R. 2000. Reverse vaccinology. Curr. Opin. Microbiol. 3:445-450.
50. Reche, P. A., J. P. Glutting, and E. L. Reinherz. 2002. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol. 63:701-709.
51. Reche, P. A., G. J., H. Zhang, and E. L. Reinherz. 2004. Enhancement to the RankPep resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 56:405-419.
52. Sette, A., and J. Fikes. 2003. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15:461-470.
53. Sette, A., and B. Peters. 2007. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr. Opin. Immunol. 19:106-110.
54. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, J. Sidney, M. F. del Guercio, S. Southwood, R. T. Kubo, R. W. Chesnut, H. M. Grey, and F. V. Chisari. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153:55865592.
55. Sidney, J., S. Southwood, C. Oseroff, M. F. Del Guercio, A. Sette, and H. Grey. 2001. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. 18:3.1-3.19.
56. Skendros, P., P. Boura, F. Kamaria, and M. Raptopoulou-Gigi. 2006. CD80/ CD28 co-stimulation in human brucellosis. Clin. Exp. Immunol. 146:400-408.
57. Suraud, V., I. Jacques, M. Olivier, and L. A. Guilloteau. 2008. Acute infec-IFN-gamma producing cells in peripheral and mucosal lymph nodes in sheep. Microbes Infect. 10:1370-1378.
58. + T cells. Int. Immunol. 5:877-883.
59. Talaat, A. M., P. Hunter, and S. A. Johnston. 2000. Genome-directed primers for selective labeling of bacterial transcripts for DNA microarray analysis. Nat. Biotechnol. 18:679-682.
60. Tatusov, R. L., N. D. Fedorova, J. D. Jackson, A. R. Jacobs, B. Kiryutin, E. V. Koonin, D. M. Krylov, R. Mazumder, S. L. Mekhedov, A. N. Nikolskaya, B. S. Rao, S. Smirnov, A. V. Sverdlov, S. Vasudevan, Y. I. Wolf, J. J. Yin, and D. A. Natale. 2003. The COG database: an updated version includes eukaryotes. BMC Bioinform. 4:41.
61. Titball, R. W. 2008. Vaccines against intracellular bacterial pathogens. Drug Discov. Today 13:596-600.
62. van der Most, R. G., A. Sette, C. Oseroff, J. Alexander, K. Murali-Krishna, L. L. Lau, S. Southwood, J. Sidney, R. W. Chesnut, M. Matloubian, and R. Ahmed. 1996. Analysis of cytotoxic T-cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157:5543-5554.
63. Vrioni, G., G. Pappas, E. Priavali, C. Gartzonika, and S. Levidiotou. 2008. An eternal microbe: Brucella DNA load persists for years after clinical cure. Clin. Infect. Dis. 46:e131-136.
64. Weynants, V., K. Walravens, C. Didembourg, P. Flanagan, J. Godfroid, and J. J. Letesson. 1998. Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle. Vet. Immunol. Immunopathol. 66:309-320.
65. Yingst, S., and D. L. Hoover. 2003. T-cell immunity to brucellosis. Crit. Rev. Microbiol. 29:313-331.